drugset / Trial / NCT05725070
Phase 0/1 Study of 212Pb-NG001 in mCRPC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.
Timeline
- Start
- 2023-03-06
- Primary completion
- 2023-07-06
- Completion
- 2023-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 212Pb-NG001 | Other / unclassified | 10 mbq | Intravenous |